Company Overview
Aditxt, Inc. operates as a commercial-stage biotechnology entity focused on the discovery and development of products across critical healthcare domains including immune health, precision health, population health, women's health, and neurologic health. The company has engineered AditxtScore tools designed to assist individuals in understanding, managing, and monitoring their immune profiles. Within the broader Healthcare sector and specifically the Biotechnology industry, the firm functions as a specialized developer aiming to translate scientific findings into marketable health solutions. As of the latest available data, the company possesses a market capitalization of $419,463, generates annual revenue of $5,945, and employs a workforce of 26 individuals. These valuation and revenue figures indicate that Aditxt is a micro-cap enterprise with a very small market presence, suggesting that its financial operations are currently limited in scale relative to larger established pharmaceutical or biotech peers. The minimal employee count combined with the low market capitalization reflects the early-stage nature of its commercial activities, where the primary focus remains on product development rather than extensive commercial infrastructure or market penetration.
Financial Health
The company reports a trailing twelve-month revenue of $5,945 alongside a net income of $-42,239,152 and an EBITDA of $-20,184,174. The substantial disparity between the minimal revenue figure and the massive negative net income reveals a cost structure heavily weighted toward research and development expenses, administrative overhead, or potential impairment charges that far exceed current sales. Free cash flow stands at $-9,754,437, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity for shareholders or debt repayment. An analysis of the three provided margin metrics shows a gross margin of 0.0%, an operating margin of -419870.3%, and a profit margin of 0.0%. The gross margin of 0.0% suggests that the cost of goods sold is consuming all revenue, while the extreme negative operating margin highlights severe operational inefficiencies or high fixed costs relative to the tiny revenue base. The company holds cash of $163,041 but carries debt of $5.67M, resulting in a debt-to-equity ratio of N/A due to the lack of positive equity. Despite holding some cash on hand, the debt load significantly outweighs liquid assets, indicating a highly leveraged balance sheet rather than a conservative one. Furthermore, the current ratio is recorded at 0.02, a figure that signals severe short-term liquidity constraints and an inability to meet current liabilities with current assets. Return on Equity is N/A because the company lacks positive equity, while the Return on Assets is -61.7%, revealing that management's efforts are currently destroying asset value rather than generating returns.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A, while the forward P/E is listed as -0.07, a discrepancy that implies the market is valuing the company based on projected negative earnings rather than historical profitability. The price-to-book ratio is -0.01, which indicates that the market is pricing the company's equity at a fraction of its book value, a scenario typical for distressed or unprofitable biotechnology firms where assets may not be liquidatable at book value. The price-to-sales ratio is 70.56, and the EV/EBITDA is -0.22; these alternative valuation metrics suggest that the market is applying a premium to the company's sales despite the lack of earnings, likely betting on potential future product approvals or partnerships that have not yet materialized. The stock has exhibited extreme volatility, with a 52-week high of $8362.00 and a 52-week low of $0.80. Given the low market cap of $419,463, the current trading price sits extremely close to the 52-week low, suggesting the stock is trading near its minimum valuation point within this volatile range. The beta value is 1.17, which means the stock's price volatility is 17% higher than the broader market, reflecting the high-risk nature of small-cap biotechnology equities that are sensitive to clinical trial outcomes and regulatory decisions.
Growth & Income
Revenue growth year-over-year is -89.1%, while earnings growth is N/A, indicating that the company is currently experiencing a contraction in sales rather than expansion. Because the earnings growth metric is unavailable due to negative or negligible earnings, a direct comparison of earnings growth versus revenue growth is not possible, but the negative revenue growth implies that the company is failing to maintain its current sales momentum in a competitive biotechnology landscape. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since there is no dividend payout, the company is not distributing profits to shareholders, which is consistent with its status as a non-dividend payer that must reinvest all available capital back into its research and development efforts to sustain operations. The overall growth and income profile of Aditxt, Inc. is characterized by significant revenue contraction and a complete absence of current income generation, highlighting the high-risk, pre-profitability stage of its commercial lifecycle.